South Korean AX specialist LG CNS is participating as a service provider in the Ministry of Health and Welfare's K-AI New Drug Development Preclinical and Clinical Model Development Project, according to a Wednesday press release.

The project is a large-scale national research and development initiative, backed by a government funding of 37.1 billion won over a period of four years.

Under the project, LG CNS will develop an AI-based clinical trial design and support platform and build an integrated management system that will link multiple AI drug development models with the help of agentic AI.

The company will apply federated learning technology, which will allow medical and research institutions to train AI models jointly without sharing raw data, the release said.

Shares of LG CNS fell nearly 2% in recent trade.